newsfilter
← Latest News
GlobeNewswire·

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial's targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries